Bertrand Boulanger

Learn More
BACKGROUND Gender differences in presentation, management and outcome in patients with ST-segment elevation myocardial infarction (STEMI) have been reported. AIM To determine whether female gender(More)
BACKGROUND Antiplatelet therapies, including prasugrel, are a cornerstone in the treatment of ST-segment elevation myocardial infarction (STEMI), but are associated with a bleeding risk. This risk(More)
BACKGROUND Minimizing delays to coronary reperfusion is critical in the management of acute myocardial infarction (AMI). AIMS To determine delays in in-hospital management and factors associated(More)
BACKGROUND Despite numerous studies in recent years, the best anticoagulant option for primary percutaneous coronary intervention (PCI) remains a matter of debate. AIMS To compare in-hospital(More)
Previous studies investigating prehospital use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction reached conflicting conclusions. The benefit of(More)
BACKGROUND Acute heart failure (AHF) complicating ST-segment elevation myocardial infarction (STEMI) is recognized as an ominous complication. Previous studies mostly reported outcomes of(More)
BACKGROUND Recent studies demonstrated the superiority of complete revascularization (CR) in patients treated by primary percutaneous coronary intervention (pPCI) in ST-elevation myocardial(More)
  • 1